Dolcyl 3 mg - 30 Tablet

Antidiabetic agent belongs to the sulfonylurea group used in the treatment of type 2 diabetes mellitus.

Take with breakfast or the first main meal of the day.

Hypoglycemia, dizziness, headache, nausea, increased serum ALT, flu-like symptoms, agranulocytosis, alopecia, anaphylaxis, angioedema, aplastic anemia, cholestatic jaundice, diarrhea, disulfiram-like reaction, dysgeusia, dyspnea, erythema, gastrointestinal pain, hemolytic anemia, hepatic failure, hepatic insufficiency, hepatic porphyria, hepatitis, hypersensitivity, hypersensitivity angiitis, hyponatremia, hypotension, immune thrombocytopenia, leukopenia, maculopapular rash, morbilliform rash, pancytopenia, porphyria cutanea tarda, pruritus, shock, skin photosensitivity, Stevens-Johnson syndrome, thrombocytopenia, urticaria, vomiting and weight gain.

-Should not be given to patients suffering from hypersensitivity to glimepiride. -All sulfonylurea drugs are capable of producing severe hypoglycemia, so use with caution with the patients having any of these risk factors: Deficient caloric intake, after severe or prolonged exercise, ethanol consumption, using more than one glucose-lowering drug, elderly patients, malnourished patients, and in patients with impaired renal or hepatic function. -In case of patients who has undergone bariatric surgery: Use an antidiabetic agent without the potential for hypoglycemia if possible; hypoglycemia may occur after gastric bypass, sleeve gastrectomy. -Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency may be at an increased risk of sulfonylurea-induced hemolytic anemia. -Use with caution in patients with hepatic impairment to avoid hypoglycemia. -Use with caution and reduce dosage in patients with renal impairment to avoid hypoglycemia. -Use with caution in elderly patients because, are more likely to develop hypoglycemia. -Not indicated for use in patients with type 1 diabetes mellitus or with diabetic ketoacidosis. -In case of over dose be ready to tell or show what was taken, how much and when it happened, and seek immediate medical attention. For additional information call us on 16676. Always tell your physician your detailed medical history.

Store at room temperature.

-Alcohol (Ethyl): Sulfonylureas may enhance the adverse/toxic effect of alcohol (Ethyl). -Alpha-lipoic acid: May enhance the hypoglycemic effect of antidiabetic agents. -Amiodarone: May enhance the hypoglycemic effect of Sulfonylureas. -Antidiabetic Agents: May enhance the hypoglycemic effect of hypoglycemia-associated agents. -Beta-Blockers: May enhance the hypoglycemic effect of Sulfonylureas. -Carbocisteine: Sulfonylureas may enhance the adverse/toxic effect of carbocisteine. -Chloramphenicol (Systemic): May increase the serum concentration of Sulfonylureas. -Clarithromycin: May enhance the hypoglycemic effect of Sulfonylureas. -Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of antidiabetic agents. -Glucagon-Like Peptide-1 Agonists: May enhance the hypoglycemic effect of Sulfonylureas. -Miconazole (Oral): May enhance the hypoglycemic effect of Sulfonylureas. -Monoamine oxidase inhibitors: May enhance the hypoglycemic effect of agents with blood glucose lowering effects. -Quinolones: May enhance the hypoglycemic effect of agents with blood glucose lowering effects. -Salicylates: May enhance the hypoglycemic effect of agents with blood glucose lowering effects. -Selective serotonin reuptake inhibitors: May enhance the hypoglycemic effect of agents with blood glucose lowering effects. -Sulfonamide antibiotics: May enhance the hypoglycemic effect of Sulfonylureas. -Tetracyclines: May enhance the hypoglycemic effect of Sulfonylureas. -Thiazide diuretics: May diminish the therapeutic effect of antidiabetic agents. -Vitamin K antagonists (eg, warfarin): Sulfonylureas may enhance the anticoagulant effect of vitamin K antagonists. -Voriconazole: May increase the serum concentration of Sulfonylureas.

-Information related to the use of glimepiride during pregnancy is limited. Agents other than glimepiride are currently recommended to treat diabetes mellitus in pregnancy. -It is not known if glimepiride is present in breast milk. the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. -Ask your physician before taking any medication during pregnancy and lactation.